SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE:A) today introduced the AriaMx System, the first instrument for real-time polymerase chain-reaction (PCR) that features easily-changeable optics cartridges for genotyping via high-resolution melt, gene-expression analysis, pathogen detection, and a variety of complex research applications.
“Expanding functionality of this innovative system is as easy as replacing a printer’s toner cartridge,” said Alessandro Borsatti, senior director of marketing for Agilent’s Diagnostics and Genomics group. “The instrument is set up to accommodate detection and visualization of up to six fluorophores, and our unique modular design also enables easy expansion if additional fluors are required.”
Expandable cartridges enable a modular instrument format and allow users to customize the system quickly and efficiently, with as many or as few filters needed to suit their application needs. This modularity makes the system ideal for core labs and principal investigators who run multiple types of applications and provides them with greater flexibility when matching the system to both their current and future needs.
- The AriaMx system can multiplex up to six channels and deliver higher optical resolution for crisp and clear data capture in each channel.
- Rapid cycle time and ultra-fast brilliant qPCR reagents enable rapid, comprehensive workflow.
- An onboard diagnostic system—the most comprehensive in the industry—provides two modes: a quick pre-test, which takes about one minute to cover more than 60 performance attributes, and a comprehensive 30-minute test, which covers more than 120 attributes. The onboard diagnostics can pinpoint potential problem points before they become serious.
- Easy-to-use software builds off of Stratagene’s familiar intuitive interface and enables researchers to confidently set up, view and analyze data from any assay.
- The system also includes HRM capabilities and advanced reporting features.
“We are honored to bring to market once again the strong enzyme engineering expertise and precision instruments and software for which Stratagene was renowned, and carry that forward with Agilent’s advanced innovations in laboratory technology,” said Jacob Thaysen, vice president and general manager of Agilent’s Diagnostics and Genomics group.
Product validation was conducted by a selection of global beta customers who processed more than 100,000 samples across 14 different assays and multiple chemistries.
For more information on the AriaMx visit www.agilent.com/genomics/ariamx.
About Agilent Technologies
Agilent Technologies Inc. (NYSE:A) is a leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com.
In September 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. On Aug. 1, 2014, the company’s electronic measurement business began operating as Keysight Technologies, Inc., a wholly owned subsidiary. The separation is expected to be completed in early November 2014.
This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding the separation of Agilent’s electronic measurement business; future revenues, earnings and profitability; the future demand for the company’s products and services; and customer expectations. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of our customers’ businesses; unforeseen changes in the demand for current and new products, technologies, and services; customer purchasing decisions and timing, and the risk that we are not able to realize the savings expected from integration and restructuring activities.
In addition, other risks that Agilent faces include those detailed in Agilent’s filings with the Securities and Exchange Commission, including our latest Form 10-K and Form 10-Q. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.
NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.